Neuroimaging of Peptide-based Vaccine Therapy in Pediatric Brain Tumors
A. D. Furtado, R. Ceschin, S. Blüml, G. Mason, R. I. Jakacki, H. Okada, I. F. Pollack, and A. Panigrahy, “Neuroimaging of Peptide-based Vaccine Therapy in Pediatric Brain Tumors,” Neuroimaging Clin. N. Am., vol. 27, no. 1, pp. 155–166, Feb. 2017.PMID: 27889021 PMCID: PMC5127439 [Available on 2018-02-01] DOI: 10.1016/j.nic.2016.09.002
The potential benefits of peptide-based immunotherapy for pediatric brain tumors are under investigation. Treatment-related heterogeneity has resulted in radiographic challenges, including pseudoprogression. Conventional MR imaging has limitations in assessment of different forms of treatment-related heterogeneity, particularly regarding distinguishing true tumor progression from efficacious treatment responses. Advanced neuroimaging techniques, including diffusion magnetic resonance (MR), perfusion MR, and MR spectroscopy, may add value in the assessment of treatment-related heterogeneity. Observations suggest that recent delineation of specific response criteria for immunotherapy of adult brain tumors is likely relevant to the pediatric population and further validation in multicenter pediatric brain tumor peptide-based vaccine studies is warranted.